The uniting paradigm in our current aetiological understanding of the dystroglycanopathies is a disruption of dystroglycan–ECM engagement. The gene discussed is DAG1; the disease is neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.